isoprenaline Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
bronchodilators, phenethylamine derivatives 1499 7683-59-2

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • isoprenaline
  • isoproterenol
  • isoproterenol hydrochloride
  • DL-Isoproterenol
  • isoprenalin
  • isoprenaline sulfate
  • DL-isoprenaline hydrochloride
  • isoproterenol sulfate
  • isoproterenol HCl
  • DL-isoprenaline HCl
Isopropyl analog of EPINEPHRINE; beta-sympathomimetic that acts on the heart, bronchi, skeletal muscle, alimentary tract, etc. It is used mainly as bronchodilator and heart stimulant.
  • Molecular weight: 211.26
  • Formula: C11H17NO3
  • CLOGP: 0.15
  • LIPINSKI: 0
  • HAC: 4
  • HDO: 4
  • TPSA: 72.72
  • ALOGS: -1.56
  • ROTB: 4

  • Status: OFP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
90 mg O
90 mg P
0.64 mg Inhal.aerosol
10 mg Inhal.solution
40 mg O

ADMET properties:

PropertyValueReference
MRTD (Maximum Recommended Therapeutic Daily Dose) 0.79 ┬ÁM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BDDCS (Biopharmaceutical Drug Disposition Classification System) 1 Hosey CM, Chan R, Benet LZ
BA (Bioavailability) 0 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution) 1.50 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 56 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 0.71 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 0.41 hours Lombardo F, Berellini G, Obach RS

Approvals:

DateAgencyCompanyOrphan
March 9, 1956 FDA

FDA Adverse Event Reporting System (Female)

None

FDA Adverse Event Reporting System (Male)

None

Pharmacologic Action:

SourceCodeDescription
ATC C01CA02 CARDIOVASCULAR SYSTEM
CARDIAC THERAPY
CARDIAC STIMULANTS EXCL. CARDIAC GLYCOSIDES
Adrenergic and dopaminergic agents
ATC R03AB02 RESPIRATORY SYSTEM
DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES
ADRENERGICS, INHALANTS
Non-selective beta-adrenoreceptor agonists
ATC R03CB01 RESPIRATORY SYSTEM
DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES
ADRENERGICS FOR SYSTEMIC USE
Non-selective beta-adrenoreceptor agonists
ATC R03AK02 RESPIRATORY SYSTEM
DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES
ADRENERGICS, INHALANTS
Adrenergics in combination with corticosteroids or other drugs, excl. anticholinergics
ATC R03CB51 RESPIRATORY SYSTEM
DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES
ADRENERGICS FOR SYSTEMIC USE
Non-selective beta-adrenoreceptor agonists
FDA MoA N0000000245 Adrenergic beta-Agonists
FDA EPC N0000175555 beta-Adrenergic Agonist
MeSH PA D018663 Adrenergic Agents
MeSH PA D000322 Adrenergic Agonists
MeSH PA D000318 Adrenergic beta-Agonists
MeSH PA D018927 Anti-Asthmatic Agents
MeSH PA D001993 Bronchodilator Agents
MeSH PA D002316 Cardiotonic Agents
MeSH PA D002317 Cardiovascular Agents
MeSH PA D018377 Neurotransmitter Agents
MeSH PA D018373 Peripheral Nervous System Agents
MeSH PA D020011 Protective Agents
MeSH PA D019141 Respiratory System Agents
MeSH PA D013566 Sympathomimetics
CHEBI has role CHEBI:35522 beta-adrenergic receptor agonist
CHEBI has role CHEBI:35523 bronchodilator agents
CHEBI has role CHEBI:35524 sympathomimetic
CHEBI has role CHEBI:38147 cardiotonic drugs

Drug Use (View source of the data)

DiseaseRelationSNOMED_IDDOID
Hypovolemic shock indication 39419009
Low cardiac output syndrome indication 44088000
Common cold indication 82272006 DOID:10459
Atrioventricular block indication 233917008 DOID:0050820
Cardiac arrest indication 410429000 DOID:0060319
Syncope due to Heart Block indication
Thick Bronchial Secretions indication
Tachyarrhythmia contraindication 6285003
Myocardial infarction contraindication 22298006 DOID:5844
Hyperthyroidism contraindication 34486009 DOID:7998
Hypertensive disorder contraindication 38341003 DOID:10763
Diabetes mellitus contraindication 73211009 DOID:9351
Angina pectoris contraindication 194828000
Chronic myocardial ischemia contraindication 413844008 DOID:3393
Disorder of coronary artery contraindication 414024009
Digitalis Toxicity with AV Conduction Defects contraindication
Atrioventricular Conduction Defect contraindication
Tachycardia due to Digitalis Toxicity contraindication

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 9.97 acidic
pKa2 12.82 acidic
pKa3 13.92 acidic
pKa4 8.94 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Beta-1 adrenergic receptor GPCR AGONIST EC50 9 WOMBAT-PK CHEMBL
Beta-2 adrenergic receptor GPCR AGONIST EC50 9.80 WOMBAT-PK CHEMBL
Beta-3 adrenergic receptor GPCR AGONIST EC50 8.50 WOMBAT-PK
Arachidonate 15-lipoxygenase Enzyme IC50 5.75 DRUG MATRIX
Beta-2 adrenergic receptor GPCR Ki 6.87 CHEMBL
Beta-1 adrenergic receptor GPCR IC50 6.22 CHEMBL
Beta-2 adrenergic receptor GPCR IC50 6 CHEMBL
Beta-2 adrenergic receptor GPCR Kd 6.48 CHEMBL
Beta-2 adrenergic receptor GPCR EC50 7.54 CHEMBL
Beta-3 adrenergic receptor Unclassified AGONIST Ki 5.30 IUPHAR
Beta-3 adrenergic receptor Unclassified AGONIST Ki 5.30 IUPHAR

External reference:

IDSource
4019793 VUID
N0000147882 NUI
D01390 KEGG_DRUG
51-30-9 SECONDARY_CAS_RN
4018235 VANDF
4018236 VANDF
4019793 VANDF
C0022245 UMLSCUI
CHEBI:31453 CHEBI
5FW PDB_CHEM_ID
CHEMBL434 ChEMBL_ID
CHEMBL1711 ChEMBL_ID
CHEMBL3989521 ChEMBL_ID
DB01064 DRUGBANK_ID
D007545 MESH_DESCRIPTOR_UI
5807 PUBCHEM_CID
536 IUPHAR_LIGAND_ID
4201 INN_ID
L628TT009W UNII
6054 RXNORM
2959 MMSL
4931 MMSL
4932 MMSL
71960 MMSL
d00697 MMSL
001778 NDDF
001779 NDDF
001780 NDDF
29301006 SNOMEDCT_US
372781009 SNOMEDCT_US
49602000 SNOMEDCT_US
57845006 SNOMEDCT_US

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Isuprel HUMAN PRESCRIPTION DRUG LABEL 1 0187-4330 INJECTION, SOLUTION 0.20 mg INTRAVENOUS NDA 19 sections
ISOPROTERENOL HYDROCHLORIDE HUMAN PRESCRIPTION DRUG LABEL 1 0548-9501 INJECTION, SOLUTION 0.20 mg INTRAVENOUS ANDA 19 sections
ISOPROTERENOL HYDROCHLORIDE HUMAN PRESCRIPTION DRUG LABEL 1 0548-9502 INJECTION, SOLUTION 0.20 mg INTRAVENOUS ANDA 19 sections
Isoproterenol Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 14789-011 INJECTION, SOLUTION 0.20 mg INTRAMUSCULAR ANDA 19 sections
Isoproterenol Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 14789-015 INJECTION, SOLUTION 0.20 mg INTRAMUSCULAR ANDA 19 sections
Isoproterenol Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 42571-294 INJECTION 0.20 mg INTRAVENOUS ANDA 18 sections
Isoproterenol Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 42571-330 INJECTION 0.20 mg INTRAVENOUS ANDA 18 sections
Isoproterenol Hydrochloride Human Prescription Drug Label 1 55150-316 INJECTION, SOLUTION 0.20 mg INTRAVENOUS ANDA 18 sections
Isoproterenol Hydrochloride Human Prescription Drug Label 1 55150-317 INJECTION, SOLUTION 1 mg INTRAVENOUS ANDA 18 sections
Isoproterenol Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 68682-433 INJECTION, SOLUTION 0.20 mg INTRAVENOUS NDA authorized generic 19 sections
ISOPROTERENOL HUMAN PRESCRIPTION DRUG LABEL 1 69097-521 INJECTION, SOLUTION 0.20 mg INTRACARDIAC ANDA 11 sections
ISOPROTERENOL HUMAN PRESCRIPTION DRUG LABEL 1 69097-522 INJECTION, SOLUTION 1 mg INTRACARDIAC ANDA 11 sections
Isoproterenol Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 70121-1604 INJECTION, SOLUTION 0.20 mg INTRACARDIAC ANDA 18 sections
Isoproterenol Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 70121-1605 INJECTION, SOLUTION 1 mg INTRACARDIAC ANDA 18 sections